May 18, 2017
Asahi Kasei Pharma Corp.

Asahi Kasei Pharma today obtained approval for an extension of the maximum duration of treatment for the osteoporosis drug Teribone™ 56.5 µg subcutaneous injection (generic name: teriparatide acetate) from 72 weeks to 24 months.

Sold in Japan since November 2011 with treatment approved for a duration of up to 72 weeks, Teribone™ is an osteoporosis drug that facilitates bone formation, and used for the treatment of osteoporosis with high risk of fracture. Asahi Kasei Pharma filed an application on July 22, 2016, to Japan's Ministry of Health, Labor and Welfare for approval to extend the maximum treatment period to 24 months.

Asahi Kasei Pharma believes that an extension of the maximum duration of treatment for Teribone™ will further enhance the treatment of osteoporosis.

IndicationOsteoporosis with high risk of fractureDosage and administrationFor adults, ordinarily administered in a single 56.5 µg injection once a week for up to 24 months.CharacteristicsThe active ingredient is teriparatide, which is peptide fragment 1-34 of the N-terminal region of human parathyroid hormone. Administered once a week, it facilitates bone formation by activating osteoblasts, which inhibits fracture through increased bone strength with both improved bone quality and increased bone mass.


Asahi Kasei Corporation published this content on 18 May 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 18 May 2017 06:08:31 UTC.

Original documenthttp://www.asahi-kasei.co.jp/asahi/en/news/2017/e170518.html

Public permalinkhttp://www.publicnow.com/view/F2055299EDED144D766B46F980C04F7EEC3FF1C1